ResMed's Cheap Exit From US Software Signals AI Is Rewriting the Rules of Sleep and Respiratory Care

ResMed, the Australian medical device giant long considered one of the most software-forward companies in respiratory and sleep health, has sold its US software business at what analysts are characterizing as a below-market valuation. The move, reported by the Australian Financial Review, comes as the company faces a mounting AI threat that is forcing leadership to reassess where its competitive moat actually lies.

The Strategic Retreat

The decision to divest the software unit cheaply rather than hold or develop it further is a striking admission that the landscape has shifted beneath ResMed's feet. For years, the company's SaaS platform — which supports remote patient monitoring and therapy adherence for conditions like sleep apnea and COPD — was considered a durable revenue stream and a key differentiator against hardware-only competitors. Selling it at a discount suggests the unit's long-term value has been undermined faster than anticipated, likely by the emergence of AI-native platforms capable of delivering similar or superior monitoring and adherence insights at a fraction of the build-and-maintenance cost.

Why AI Changes the Calculus

The aging population is the core addressable market for sleep apnea and respiratory care technology. Older adults account for a disproportionate share of CPAP users, home oxygen patients, and chronic respiratory disease diagnoses — and it is precisely this segment that is driving demand for remote monitoring and caregiver-integrated health management tools. AI models trained on longitudinal patient data can now surface therapy compliance risks, flag deteriorating respiratory patterns, and generate clinical decision support in ways that legacy SaaS architectures struggle to match. For ResMed, maintaining a traditional software business while AI-native competitors move faster and cheaper became an increasingly untenable position. The sale, whatever its price, frees capital to focus on hardware innovation and potentially a new generation of AI-integrated device ecosystems.

Market Context for Elder Care Tech

ResMed's pivot is a signal the broader agetech and medtech industries should read carefully. Software platforms built in the 2010s to serve aging patients through subscription models are now facing a structural challenge: the value proposition that justified their margins is being commoditized by AI. Investors backing aging-in-place technology, remote patient monitoring, and chronic disease management platforms will increasingly ask whether a product is genuinely AI-native or simply an older SaaS tool with a machine learning layer applied on top. The distinction matters enormously for defensibility.

The ResMed divestiture may be among the first high-profile examples of a legacy medtech company acknowledging that reality in the most concrete way possible — and it almost certainly will not be the last.